Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
V0101
- Development stage
- Unknown
- Lead developer
- Inmunova
- Modality
- Recombinant Proteins and Enzymes, Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
V0101 is a recombinant chimeric protein developed by Inmunova in collaboration with Chemo Research (Insud Pharma) for the treatment of hemolytic uremic syndrome (HUS) resulting from Shiga toxin-producing Escherichia coli (STEC) infection. The therapeutic consists of VHH domains, or nanobodies, derived from camelids that have been engineered to neutralize both Shiga toxin 1 (Stx1) and Shiga toxin 2 (Stx2). By binding with high affinity to the toxins in the circulation, V0101 prevents them from entering host cells via the Gb3 receptor. This intervention aims to block the systemic toxemia that leads to the life-threatening complications of HUS, including acute kidney injury and thrombocytopenia. V0101 is currently being investigated in Phase 2 clinical trials as a potential first-in-class passive immunotherapy for STEC-infected patients at risk of progressing to HUS.
- Other names
- anti-Shiga toxinanti-Shiga toxin VHHanti-Stx VHHVHH-anti-Stx
02
Targets
Stx2 (Shiga toxin 2)Stx2e (Shiga toxin 2e)Stx1B (Shiga toxin 1 subunit B)
Beyond the preview
Go deeper on V0101.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on V0101.